CYP2D6 rs41475656: Understanding the *41 Splice Defect

What each genotype means

What is the rs41475656 Variant?

The rs41475656 variant is a single-nucleotide polymorphism (SNP) found within the CYP2D6 gene, located on chromosome 22. In the context of pharmacogenomics, this specific SNP is a defining component of the CYP2D6*41 allele. The variant involves a G to A substitution at position 2988, which creates a splicing defect. This defect interferes with the normal processing of the gene's instructions, resulting in a significant reduction in the amount of functional CYP2D6 enzyme produced by the cell. Because the CYP2D6 enzyme is essential for breaking down a wide variety of therapeutic drugs, variations that alter its expression or function can lead to differences in how quickly or effectively a person's body clears these medications from their system.

The Role of the CYP2D6 Gene

The CYP2D6 gene encodes a member of the cytochrome P450 family of enzymes, which are primarily responsible for the metabolism of approximately 20% to 25% of all clinically used drugs. This includes a broad spectrum of medications used in psychiatry, pain management, oncology, and cardiology, such as SSRIs, codeine, and tamoxifen. The gene is highly polymorphic, meaning it exists in many different forms across the human population. These variations range from single-nucleotide changes to complete gene deletions or duplications. Because the enzyme's activity level determines the concentration of a drug in the bloodstream, individuals with reduced-function alleles like *41 may experience different drug responses compared to those with fully functional enzyme activity. Understanding these variations is a cornerstone of personalized medicine, as it helps clinicians predict potential efficacy or adverse reactions.

Research and Clinical Evidence

Research into the CYP2D6*41 allele, marked by rs41475656, indicates that it is a reduced-function variant. Scientific literature, including studies published in journals like Frontiers in Pharmacology, suggests that the splicing defect associated with this variant can reduce enzyme expression by as much as 90% in in vitro models. While clinical guidelines from organizations like the Clinical Pharmacogenetics Implementation Consortium (CPIC) assign an activity score to this variant, some researchers argue that the current assigned scores may not fully capture the complexity of its impact in real-world clinical settings. The evidence for this variant is considered limited in terms of its standalone predictive power, as drug response is often influenced by multiple factors, including other genetic variants, drug-drug interactions, and environmental factors. Consequently, while the association with reduced metabolism is well-documented, it is not a definitive diagnostic tool on its own.

What You Can Do With This Information

If you have received information about your CYP2D6 genotype, it is important to view it as one piece of a much larger puzzle. Genetic testing for pharmacogenomics can provide insights into how your body might process certain medications, but it should never be used to make independent decisions about your health or treatment. You cannot use this information to diagnose a condition or to start, stop, or change the dosage of any prescribed medication. If you are concerned about how a medication is affecting you, or if you are interested in how your genetics might influence your treatment plan, the best course of action is to discuss these results with your clinician or a pharmacist. They are trained to interpret these findings in the context of your full medical history, current medications, and overall health goals to ensure your treatment is safe and effective.

Frequently asked questions

Sources & further reading

Related variants in CYP2D6